GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lung Cancer Conference. Pasi Jänne MD PhD from the Dana-Farber Cancer Institute in Boston MA, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine at Harvard Medical School, gave Oncology Times reporter Peter Goodwin the latest details about the clinical potential of this therapy.
You may also like...
Time from nephrectomy to metastasis confirmed as prognostic in patients with renal cell carcinoma treated with targeted therapies 13 Feb, 2014 Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time 24 Mar, 2015 IGNITE Study: More Asians than Russians with Mutant EGFR Lung Adenocarcinoma; Adjuvant Erlotinib for Stage IIIA-N2 Disease 27 Apr, 2015 Diabetes increases risk of breast and colon cancer 4 Oct, 2013
- Previous story CD8+ Cell Infiltration for Prognosis in Non-Small Cell Lung Cancer; Checkpoint Inhibition 2nd/3rd-line in Mesothelioma
- Next story Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014